HOWL
Werewolf Therapeutics, Inc.1.0800
+0.0500+4.85%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
52.42MP/E (TTM)
-Basic EPS (TTM)
-1.62Dividend Yield
0%Recent Filings
8-K
Board member passes, Nasdaq noncompliance
Werewolf Therapeutics disclosed the passing of Board member Dr. Alon Lazarus on September 30, 2025, leaving its Audit Committee with only two members and breaching Nasdaq's three-member requirement. The company notified Nasdaq on October 2, 2025, securing a cure period until the next annual meeting or September 30, 2026. Board plans to appoint an independent director soon. This vacancy disrupts committee oversight, yet compliance looms assured.
10-Q
Q2 FY2025 results
Werewolf Therapeutics reported no revenue for Q2 FY2025 ended June 30, 2025, consistent with its clinical-stage biotech focus, while research and development expenses rose year-over-year due to ongoing pipeline advancement, and general and administrative costs held steady. The company posted an operating loss that widened sequentially from Q1, driven by higher R&D investments, with net loss differing mainly from stock-based compensation and interest expenses as noted in the statements. Cash reserves stood at quarter-end, supporting operations without debt or revolver details disclosed. No free cash flow provided, as capex not broken out. Hired Steven Bloom as Chief Business Officer effective April 16, 2025, with a $400,000 base salary and equity inducement grant of 201,720 options vesting over four years. Regulatory hurdles in clinical trials pose ongoing risks.
8-K
Q2 results and pipeline update
Werewolf Therapeutics reported Q2 2025 financials, showing $77.6 million in cash sufficient into Q4 2026, down from $92.0 million in Q1, with R&D expenses dropping to $13.1 million from $15.3 million year-over-year and a net loss of $18.0 million. The company advances WTX-124's Phase 1/1b trial, targeting interim data in Q4 2025 for melanoma and renal cell carcinoma patients, while planning FDA talks on registrational paths. WTX-330's Phase 1b/2 trial enrolls actively, with dosing set by year-end; they unveiled WTX-1011, a masked STEAP1 T-cell engager for prostate cancer, reducing cytokine risks. Cash burn persists, but milestones loom.
8-K
Bylaws updated, directors elected
Werewolf Therapeutics updated its bylaws on June 12, 2025, refining stockholder nomination procedures, clarifying proposal updates, and specifying meeting presiders—changes that tighten governance without fanfare. At the same annual meeting, shareholders elected Briggs Morrison, Michael Sherman, and Anil Singhal as Class I directors for three-year terms, with strong support exceeding 19 million votes each, while broker non-votes hit 8.1 million. They also ratified Ernst & Young as auditors for 2025, passing overwhelmingly at 33.5 million for versus just 31,000 against. Routine housekeeping bolsters board continuity.
8-K
Nasdaq bid price deficiency notice
Werewolf Therapeutics received a Nasdaq notice on May 13, 2025, for its common stock closing below $1.00 per share over 30 consecutive business days, violating the minimum bid requirement. The company has 180 days until November 10, 2025, to lift the price above $1.00 for 10 straight business days. No immediate delisting looms, but failure risks transfer to the Nasdaq Capital Market or appeal. It plans to monitor and explore fixes, yet success isn't guaranteed.
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CTMX
CytomX Therapeutics, Inc.
4.25+0.12
HCWB
HCW Biologics Inc.
1.78-0.09
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
JANX
Janux Therapeutics, Inc.
14.65-0.47
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
TIL
Instil Bio, Inc.
11.25+0.13
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04
XLO
Xilio Therapeutics, Inc.
0.65+0.00